Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer [Yahoo! Finance]
Tenax Therapeutics, Inc. (TENX)
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.tenaxthera.com
Company Research
Source: Yahoo! Finance
CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience across management and corporate finance roles in the healthcare industry. He will replace Thomas McGauley, who has served as interim CFO since December 2024. “Tom brings decades of experience as a CFO, leading strategic finance functions, growing and integrating organizations, and launching products at multiple healthcare companies. He joins at a crucial moment in Tenax's evolution, as we expand our registrational program globally and begin building out strategic capabilities key to levosimendan's future as potentially the first available therapy for PH-H
Show less
Read more
Impact Snapshot
Event Time:
TENX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TENX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TENX alerts
High impacting Tenax Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TENX
News
- Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerGlobeNewswire
- Tenax Therapeutics: A Binary Bet With Heavy Downside Likely [Seeking Alpha]Seeking Alpha
- Tenax Therapeutics (TENX) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $35.00 price target on the stock.MarketBeat
- Tenax Therapeutics (TENX) had its price target raised by Guggenheim from $25.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- Tenax Therapeutics (TENX) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
TENX
Sec Filings
- 4/22/26 - Form ARS
- 4/22/26 - Form DEFA14A
- 4/22/26 - Form DEF
- TENX's page on the SEC website